Related Experiment Video

Updated: Jun 13, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

[Concerning a new approach toward prostatic cancer]

Roland Muntz1

  • 1L'Association Nationale des Malades du Cancer de la Prostate. info@anamacap.fr

Revue De L'Infirmiere
|April 14, 2010
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: Jun 13, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

[Münchhausen syndrome: a psychological condition that needs to be identified and treated].

Revue de l'infirmiere·2026

[Gender-based biases: a study of bias in nurses' body language in an emergency setting].

Revue de l'infirmiere·2026

[Taking action for women's hearts].

Revue de l'infirmiere·2026

[Cardiovascular risk: women die from cardiovascular disease more often than men].

Revue de l'infirmiere·2026

[Rehabilitation for coronary heart disease: the role of physical therapy and other members of the rehabilitation team].

Revue de l'infirmiere·2026

[Nursing care throughout the coronary patient's treatment journey].

Revue de l'infirmiere·2026

Patterns of Colorectal Cancer Diagnosis in Older Adults: A SEER-Medicare Analysis of Health and Economic Impact of Missed Screening Opportunities.

Journal of surgical oncology·2026

US real-world biomarker testing differences and treatment choice in advanced ovarian cancer: results of a retrospective study.

Future oncology (London, England)·2026

Renal Dysfunction Across Etiologies of Chronic Liver Disease: A Cross-Sectional Study From a Tertiary Care Center.

Cureus·2026

A Case of Cecal Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm Requiring Adjuvant Chemotherapy Based on Comprehensive Pathological Assessment.

Surgical case reports·2026

Epitranscriptomic control of epithelial-mesenchymal transition in cancer: mechanisms, plasticity, and therapeutic opportunities.

Frontiers in cell and developmental biology·2026

A cross-validated deep learning framework for automated detection of DMBA-induced ovarian cancer from histopathological images with CA-125 biomarker support.

Frontiers in artificial intelligence·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us